利拉鲁肽联合替格瑞洛对老年2型糖尿病伴冠心病患者的临床疗效观察OA
Clinical Efficacy Observation of Liraglutide Combined with Ticagrelor in the Treatment of Elderly Type 2 Diabetes Mellitus Patients with Coronary Heart Disease
目的:探讨利拉鲁肽联合替格瑞洛对老年2型糖尿病(T2DM)伴冠心病(CHD)患者的影响.方法:选取 2020 年 1 月—2021 年 1 月武汉中西医结合骨科医院收治的 70 例老年T2DM伴CHD患者为研究对象,按随机数字表法分为对照组(n=35)和研究组(n=35),对照组给予盐酸二甲双胍及替格瑞洛治疗,研究组给予利拉鲁肽联合替格瑞洛治疗,比较两组干预前后的血糖指标[空腹血糖(FPG)、糖化血红蛋白(HbA1c)]、心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、舒张早期二尖瓣血流速度/舒张晚期二尖瓣血流速度(E/A)]、炎症指标[白细胞介素-6(IL-6)、内皮素-1(ET-1)、肿瘤坏死因子-α(TNF-α)]、血管内皮细胞相关因子[血管脂肪抑制素(Vaspin)、生长激素释放肽(Ghrelin)及一氧化氮(NO)].结果:干预前,两组血糖指标、心功能指标、炎症指标、血管内皮细胞相关因子比较,差异均无统计学意义(P>0.05).干预后,研究组FPG、HbA1c水平均低于对照组,差异均有统计学意义(P<0.05);干预后,研究组LVEF、E/A均高于对照组,LVEDD低于对照组,差异均有统计学意义(P<0.05);干预后,研究组IL-6、ET-1、TNF-α水平均低于对照组,差异均有统计学意义(P<0.05);干预后,研究组Vaspin、Ghrelin、NO水平均高于对照组,差异均有统计学意义(P<0.05).结论:老年T2DM伴CHD患者应用利拉鲁肽联合替格瑞洛进行治疗,能有效改善血糖水平、心功能及血管内皮功能,减轻炎症反应.
Objective:To investigate the effect of Liraglutide combined with Ticagrelor on elderly patients with type 2 diabetes mellitus(T2DM)and coronary heart disease(CHD).Method:A total of 70 elderly patients with T2DM and CHD admitted to Wuhan Integrated Traditional Chinese and Western Medicine Orthopedic Hospital from January 2020 to January 2021 were selected as the study objects.They were divided into control group(n=35)and study group(n=35)according to random number table method.The control group was given Metformin Hydrochloride and Ticagrelor,and the study group was given Liraglutide combined with Ticagrelor.Blood glucose indexes[fasting plasma glucose(FPG),glycosylated hemoglobin(HbA1c)],cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),early diastolic mitral valve flow velocity/late diastolic mitral valve flow velocity(E/A)],inflammation indexes[interleukin-6(IL-6),endothelin-1(ET-1),tumor necrosis factor-α(TNF-α)],vascular endothelial cell related factors[vascular lipostatin(Vaspin),growth hormone releasing peptide(Ghrelin)and nitric oxide(NO)]between the two groups before and after intervention were compared.Result:Before intervention,there were no significant differences in blood glucose indexes,cardiac function indexes,inflammation indexes and vascular endothelial cell related factors between the two groups(P>0.05).After intervention,the levels of FPG and HbA1c in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After intervention,LVEF,E/A in the study group were higher than those in the control group,and LVEDD was lower than that in the control group,the differences were statistically significant(P<0.05).After intervention,the levels of IL-6,ET-1 and TNF-α in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After intervention,the levels of Vaspin,Ghrelin and NO in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion:Liraglutide combined with Ticagrelor can effectively improve blood glucose level,cardiac function and vascular endothelial function,and reduce inflammation in elderly patients with T2DM and CHD.
舒盼
武汉中西医结合骨科医院中西结合内科 湖北 武汉 430000
利拉鲁肽替格瑞洛老年2型糖尿病冠心病
LiraglutideTicagrelorElderly type 2 diabetes mellitusCoronary heart disease
《中国医学创新》 2024 (024)
5-9 / 5
评论